First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) Short Interest Update

First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 8,433 shares, a decrease of 77.9% from the November 30th total of 38,093 shares. Based on an average daily trading volume, of 30,780 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are sold short. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 30,780 shares, the days-to-cover ratio is presently 0.3 days.

First Trust NYSE Arca Biotechnology Index Fund Price Performance

First Trust NYSE Arca Biotechnology Index Fund stock traded down $0.94 during trading hours on Friday, reaching $214.13. The stock had a trading volume of 6,665 shares, compared to its average volume of 20,843. The company has a fifty day simple moving average of $203.30 and a 200-day simple moving average of $182.28. First Trust NYSE Arca Biotechnology Index Fund has a 52 week low of $141.38 and a 52 week high of $215.83. The stock has a market cap of $1.30 billion, a PE ratio of 21.72 and a beta of 0.65.

Hedge Funds Weigh In On First Trust NYSE Arca Biotechnology Index Fund

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Meridian Wealth Management LLC lifted its position in shares of First Trust NYSE Arca Biotechnology Index Fund by 1.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 3,552 shares of the company’s stock worth $637,000 after purchasing an additional 54 shares during the period. Bedell Frazier Investment Counselling LLC grew its holdings in shares of First Trust NYSE Arca Biotechnology Index Fund by 1.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 3,200 shares of the company’s stock worth $574,000 after acquiring an additional 57 shares during the period. Stratos Wealth Partners LTD. raised its position in shares of First Trust NYSE Arca Biotechnology Index Fund by 3.8% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,621 shares of the company’s stock worth $262,000 after acquiring an additional 60 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of First Trust NYSE Arca Biotechnology Index Fund by 0.8% in the 2nd quarter. First Trust Advisors LP now owns 8,393 shares of the company’s stock valued at $1,355,000 after purchasing an additional 66 shares during the period. Finally, Harbour Investments Inc. lifted its stake in shares of First Trust NYSE Arca Biotechnology Index Fund by 1.2% in the 2nd quarter. Harbour Investments Inc. now owns 5,767 shares of the company’s stock valued at $930,000 after purchasing an additional 69 shares during the period.

About First Trust NYSE Arca Biotechnology Index Fund

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is managed by First Trust.